1 / 1

RE-COVER

RE-COVER. Primary outcome (recurrent VTE or death due to VTE): 2.4% vs. 2.1% Mortality: 1.6% vs. 1.7% (p > 0.05) Major bleeding: 1.6% vs. 1.9%; Major + clinically relevant bleeding: 5.6% vs. 8.8.% (p = 0.002). (p = 0.38). (p < 0.001*).

ariel-tucker
Download Presentation

RE-COVER

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. RE-COVER Primary outcome (recurrent VTE or death due to VTE): 2.4% vs. 2.1% Mortality: 1.6% vs. 1.7% (p > 0.05) Major bleeding: 1.6% vs. 1.9%; Major + clinically relevant bleeding: 5.6% vs. 8.8.% (p = 0.002) (p = 0.38) (p < 0.001*) Trial design:Evaluated the safety and efficacy of dabigatran 150 mg twice daily vs. warfarin for the treatment of acute VTE. Patients were followed for 6 months. Results * For noninferiority 5 5 4 4 3 3 % Conclusions 2.4 % 2.1 2 2 1.9 • Dabigatran 150 mg twice daily is noninferior to warfarin for the treatment of acute VTE, with a slightly better bleeding profile • Complements other studies showing safety and efficacy of dabigatran, as compared with warfarin in other settings, such as AF 1.6 1 1 0 0 Primary endpoint Major bleeding Dabigatran (n = 1,274) Warfarin (n = 1,265) Schulman S, et al. N Engl J Med 2009;361:2342-52

More Related